{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T04:01:50Z","timestamp":1745726510285,"version":"3.40.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,10,6]],"date-time":"2024-10-06T00:00:00Z","timestamp":1728172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,6]],"date-time":"2024-10-06T00:00:00Z","timestamp":1728172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Spanish Oncology Genito-Urinary Group"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-024-03744-6","type":"journal-article","created":{"date-parts":[[2024,10,6]],"date-time":"2024-10-06T14:01:47Z","timestamp":1728223307000},"page":"2220-2231","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of COVID-19 infection on genitourinary cancer management. SOGUG-COVID-19: A spanish, multicenter, observational study"],"prefix":"10.1007","volume":"27","author":[{"given":"Natalia","family":"Vidal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel \u00c1ngel","family":"Climent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Jos\u00e9","family":"M\u00e9ndez-Vidal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgia","family":"Anguera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imanol","family":"Mart\u00ednez Salas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique","family":"Gallardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miler Andr\u00e9s","family":"Cu\u00e9llar-Rivas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Molina-Cerrillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Almudena","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejo","family":"Rodriguez-Vida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Almagro Casado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Macarena","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Montserrat","family":"Dom\u00e8nech","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mireia","family":"Mart\u00ednez Kareaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ovidio","family":"Fern\u00e1ndez Calvo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Carlos","family":"Villa Guzm\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"V\u00e1zquez Est\u00e9vez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6570-009X","authenticated-orcid":false,"given":"Ar\u00e1nzazu","family":"Gonz\u00e1lez-del-Alba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Puente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,6]]},"reference":[{"key":"3744_CR1","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S1470-2045(20)30096-6","volume":"21","author":"W Liang","year":"2020","unstructured":"Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21:335\u20137.","journal-title":"Lancet Oncol"},{"key":"3744_CR2","doi-asserted-by":"publisher","first-page":"519","DOI":"10.20892\/j.issn.2095-3941.2020.0289","volume":"17","author":"C Liu","year":"2020","unstructured":"Liu C, Zhao Y, Okwan-Duodu D, Basho R, Cui X. COVID-19 in cancer patients: risk, clinical features, and management. Cancer Biol Med. 2020;17:519\u201327.","journal-title":"Cancer Biol Med"},{"key":"3744_CR3","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41416-021-01396-9","volume":"125","author":"AF Bertuzzi","year":"2021","unstructured":"Bertuzzi AF, Ciccarelli M, Marrari A, Gennaro N, Dipasquale A, Giordano L, et al. Impact of active cancer on COVID-19 survival: a matched-analysis on 557 consecutive patients at an academic hospital in Lombardy. Italy Br J Cancer. 2021;125:358\u201365.","journal-title":"Italy Br J Cancer"},{"key":"3744_CR4","doi-asserted-by":"publisher","first-page":"e444","DOI":"10.1016\/S2468-2667(20)30146-8","volume":"5","author":"J Hewitt","year":"2020","unstructured":"Hewitt J, Carter B, Vilches-Moraga A, Quinn TJ, Braude P, Verduri A, et al. The effect of frailty on survival in patients with COVID-19 (COPE): a multicentre, European, observational cohort study. Lancet Public Health. 2020;5:e444\u201351.","journal-title":"Lancet Public Health"},{"key":"3744_CR5","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1001\/jama.2020.6775","volume":"323","author":"S Richardson","year":"2020","unstructured":"Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized With COVID-19 in the New York City area. JAMA. 2020;323:2052\u20139.","journal-title":"JAMA"},{"key":"3744_CR6","doi-asserted-by":"publisher","first-page":"44123","DOI":"10.1038\/srep44123","volume":"7","author":"Y Chen","year":"2017","unstructured":"Chen Y, Liu Y-C, Sung Y-C, Ramjiawan RR, Lin T-T, Chang C-C, et al. Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors. Sci Rep. 2017;7:44123.","journal-title":"Sci Rep"},{"key":"3744_CR7","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","volume":"395","author":"F Zhou","year":"2020","unstructured":"Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054\u201362.","journal-title":"Lancet"},{"key":"3744_CR8","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.annonc.2021.02.024","volume":"32","author":"P Grivas","year":"2021","unstructured":"Grivas P, Khaki AR, Wise-Draper TM, French B, Hennessy C, Hsu C-Y, et al. Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. Ann Oncol. 2021;32:787\u2013800.","journal-title":"Ann Oncol"},{"key":"3744_CR9","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1001\/jama.2020.2648","volume":"323","author":"Z Wu","year":"2020","unstructured":"Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China. JAMA: J Am Med Assoc. 2020;323:1239\u201342.","journal-title":"JAMA: J Am Med Assoc"},{"key":"3744_CR10","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China Lancet. 2020;395:497\u2013506.","journal-title":"China Lancet"},{"key":"3744_CR11","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1093\/jnci\/djaa168","volume":"113","author":"H Zhang","year":"2021","unstructured":"Zhang H, Han H, He T, Labbe KE, Hernandez AV, Chen H, et al. Clinical characteristics and outcomes of COVID-19-infected cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst. 2021;113:371\u201380.","journal-title":"J Natl Cancer Inst"},{"key":"3744_CR12","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.annonc.2020.03.296","volume":"31","author":"L Zhang","year":"2020","unstructured":"Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan. China Ann Oncol. 2020;31:894\u2013901.","journal-title":"China Ann Oncol"},{"key":"3744_CR13","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1158\/2159-8290.CD-20-0422","volume":"10","author":"M Dai","year":"2020","unstructured":"Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov. 2020;10:783\u201391.","journal-title":"Cancer Discov"},{"key":"3744_CR14","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/S1470-2045(20)30310-7","volume":"21","author":"K Yang","year":"2020","unstructured":"Yang K, Sheng Y, Huang C, Jin Y, Xiong N, Jiang K, et al. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study. Lancet Oncol. 2020;21:904\u201313.","journal-title":"Lancet Oncol"},{"key":"3744_CR15","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/S1470-2045(20)30201-1","volume":"21","author":"TK Burki","year":"2020","unstructured":"Burki TK. Cancer care in the time of COVID-19. Lancet Oncol. 2020;21:628.","journal-title":"Lancet Oncol"},{"key":"3744_CR16","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/S0140-6736(20)31173-9","volume":"395","author":"LY Lee","year":"2020","unstructured":"Lee LY, Cazier J-B, Angelis V, Arnold R, Bisht V, Campton NA, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet. 2020;395:1919\u201326.","journal-title":"Lancet"},{"key":"3744_CR17","doi-asserted-by":"publisher","first-page":"6656","DOI":"10.1172\/JCI141777","volume":"130","author":"GL Shah","year":"2020","unstructured":"Shah GL, DeWolf S, Lee YJ, Tamari R, Dahi PB, Lavery JA, et al. Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation. J Clin Invest. 2020;130:6656\u201367.","journal-title":"J Clin Invest"},{"key":"3744_CR18","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1002\/cam4.3692","volume":"10","author":"H Liu","year":"2021","unstructured":"Liu H, Yang D, Chen X, Sun Z, Zou Y, Chen C, et al. The effect of anticancer treatment on cancer patients with COVID-19: a systematic review and meta-analysis. Cancer Med. 2021;10:1043\u201356.","journal-title":"Cancer Med"},{"key":"3744_CR19","doi-asserted-by":"crossref","first-page":"2001431","DOI":"10.2807\/1560-7917.ES.2020.25.21.1900364","volume":"25","author":"L Redondo-Bravo","year":"2020","unstructured":"Redondo-Bravo L, Sierra Moros MJ, Mart\u00ednez S\u00e1nchez EV, Lorusso N, Carmona Ubago A, Gallardo Garc\u00eda V, et al. The first wave of the COVID-19 pandemic in Spain: characterisation of cases and risk factors for severe outcomes, as at 27 April 2020. Euro Surveill. 2020;25:2001431.","journal-title":"Euro Surveill"},{"key":"3744_CR20","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s13045-021-01205-z","volume":"14","author":"I Tsimafeyeu","year":"2021","unstructured":"Tsimafeyeu I, Volkova M, Alekseeva G, Berkut M, Nosov A, Myslevtsev I, et al. Safety and preliminary efficacy of the Gam-COVID-Vac vaccine and outcomes of SARS-CoV-2 infection in Russian patients with genitourinary malignancies. J Hematol Oncol. 2021;14:192.","journal-title":"J Hematol Oncol"},{"key":"3744_CR21","doi-asserted-by":"publisher","first-page":"10904","DOI":"10.1038\/s41598-022-14016-0","volume":"12","author":"K Kl\u00e4ser","year":"2022","unstructured":"Kl\u00e4ser K, Molteni E, Graham M, Canas LS, \u00d6sterdahl MF, Antonelli M, et al. 2022 COVID-19 due to the B.1.617.2 (Delta) variant compared to B.1.1.7 (Alpha) variant of SARS-CoV-2: a prospective observational cohort study. Sci Rep. 2022;12:10904.","journal-title":"Sci Rep"},{"key":"3744_CR22","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S2213-8587(20)30405-8","volume":"9","author":"SJ McGurnaghan","year":"2021","unstructured":"McGurnaghan SJ, Weir A, Bishop J, Kennedy S, Blackbourn LAK, McAllister DA, et al. Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland. Lancet Diabetes Endocrinol. 2021;9:82\u201393.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"3744_CR23","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1016\/S0140-6736(20)31187-9","volume":"395","author":"NM Kuderer","year":"2020","unstructured":"Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395:1907\u201318.","journal-title":"Lancet"},{"key":"3744_CR24","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S1470-2045(20)30314-4","volume":"21","author":"MC Garassino","year":"2020","unstructured":"Garassino MC, Whisenant JG, Huang L-C, Trama A, Torri V, Agustoni F, et al. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncol. 2020;21:914\u201322.","journal-title":"Lancet Oncol"},{"key":"3744_CR25","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1158\/2159-8290.CD-20-0773","volume":"10","author":"DJ Pinato","year":"2020","unstructured":"Pinato DJ, Zambelli A, Aguilar-Company J, Bower M, Sng C, Salazar R, et al. Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients. Cancer Discov. 2020;10:1465\u201374.","journal-title":"Cancer Discov"},{"key":"3744_CR26","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/S1470-2045(20)30309-0","volume":"21","author":"J Tian","year":"2020","unstructured":"Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, et al. Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study. Lancet Oncol. 2020;21:893\u2013903.","journal-title":"Lancet Oncol"},{"key":"3744_CR27","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/S1470-2045(20)30238-2","volume":"21","author":"H Mei","year":"2020","unstructured":"Mei H, Dong X, Wang Y, Tang L, Hu Y. Managing patients with cancer during the COVID-19 pandemic: frontline experience from Wuhan. Lancet Oncol. 2020;21:634\u20136.","journal-title":"Lancet Oncol"},{"key":"3744_CR28","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.3390\/cancers12092352","volume":"12","author":"AF Bertuzzi","year":"2020","unstructured":"Bertuzzi AF, Marrari A, Gennaro N, Cariboni U, Ciccarelli M, Giordano L, et al. Low incidence of SARS-CoV-2 in patients with solid tumours on active treatment: an observational study at a tertiary cancer centre in lombardy, Italy. Cancers (Basel). 2020;12:2352.","journal-title":"Cancers (Basel)"},{"key":"3744_CR29","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/S1470-2045(21)00574-X","volume":"22","author":"SF Oosting","year":"2021","unstructured":"Oosting SF, van der Veldt AAM, GeurtsvanKessel CH, Fehrmann RSN, van Binnendijk RS, Dingemans AMC, et al. mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial. Lancet Oncol. 2021;22:1681\u201391.","journal-title":"Lancet Oncol"},{"key":"3744_CR30","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1158\/2159-8290.CD-21-1072","volume":"11","author":"I Waldhorn","year":"2021","unstructured":"Waldhorn I, Holland R, Goshen-Lago T, Shirman Y, Szwarcwort-Cohen M, Reiner-Benaim A, et al. Six-month efficacy and toxicity profile of BNT162b2 vaccine in cancer patients with solid tumors. Cancer Discov. 2021;11:2430\u20135.","journal-title":"Cancer Discov"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-024-03744-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-024-03744-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-024-03744-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T06:03:22Z","timestamp":1745647402000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-024-03744-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,6]]},"references-count":30,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["3744"],"URL":"https:\/\/doi.org\/10.1007\/s12094-024-03744-6","relation":{},"ISSN":["1699-3055"],"issn-type":[{"type":"electronic","value":"1699-3055"}],"subject":[],"published":{"date-parts":[[2024,10,6]]},"assertion":[{"value":"9 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the remaining co-authors state that they do not have conflict of interest. NV has received honoraria for speaker engagements, advisory roles or continuous medical education: Sanofi, AstraZeneca, Astellas, Janssen, Roche, MSD, Ipsen, consultant: Janssen. JP has received honoraria for speaker engagements, advisory roles or continuous medical education: Astellas, AstraZeneca, Janssen, MSD, Bayer, Pfizer, Eisai, Ipsen, Sanofi, Roche, BMS, Merck, research funding: Astellas, Pfizer and consultant: Astellas, Roche. JMC declares consultant, advisory or speaker roles for Ipsen, Pfizer, Roche, Astellas, Sanofi-Genzyme, Adacap, Janssen, Eisai, Bristol-Myers Squibb. JMC has received research grants from Pfizer, IPSEN and Janssen. EG has received grant support from Astellas, Janssen, Sanofi, Bayer, Ipsen, Ferrer, Pfizer, Roche, GSK and BMS; has received consulting fees from Sanofi, Janssen, Astellas, Bayer, Ipsen, Pfizer, Roche, Novartis, Eisai, EUSA Pharma, BMS, AstraZeneca, Merck, Rovi, Daiichi Sankyo and Techdow; has received payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing, or educational events from Astellas, Janssen, Sanofi, Bayer, Ipsen, Pfizer, Roche, BMS, Rovi, Daiichi Sankyo, Leo Pharma, Menarini, Eisai, MSD, Boehringer Ingelheim, Merck, EUSA Pharma and Novartis; has received support for attending meetings and\/or travel from Astellas, Janssen, Sanofi, BMS, Bayer, Ipsen, Roche, Novartis, Pierre Fabre, Pfizer and Eisai. GA has received honoraria for speaker Roche, Ipsen, Bristol-Myers Squibb. AGA has received honoraria for consultant, speaker engagements, advisory roles or continuous medical education: Astellas, Pfizer, Astra Zeneca, Janssen, MSD, Bayer, Eisai, Ipsen, Sanofi, Roche, BMS, Merck. JMC has received investigation grants from Pfizer, Janssen and Ipsen; has received consulting fees from Ipsen, Pfizer, Roche, Sanofi, Astellas, Janssen Cilag, BMS, and EISAI; and has received support for attending meetings and\/or travel from Pfizer, BMS, and Ipsen. ARV reports serving in an advisory role for MSD, Pfizer, BMS, Astellas, Janssen, Bayer, Clovis, Ipsen, Merck and Roche; receiving honoraria or travel expenses from Pfizer, MSD, Astellas, Merck, BMS, Janssen, AstraZeneca, Ipsen, Roche, Bayer, and Sanofi Aventis; and receiving research funding from Takeda, Pfizer, and Merck. MMK has received honoraria for speaker engagements, advisory roles, support for attending meetings or continuous medical education from Roche, BMS, Janssen, MSD and Merck. AM has received honoraria for speaker engagements, advisory roles, research grant or continuous medical education from Janssen Cilag, Astellas, Sanofi, AstraZeneca, BMS, Pfizer, Roche, Pharmamar, Aveo.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This observational study was conducted in compliance with the International Ethical Guidelines for Biomedical Research Involving Human Subjects, Good Clinical Practice guidelines, and the Declaration of Helsinki, 1964, and local laws, SAS order 3470\/2009 and Organic Law 3\/2018, of December 5, on the Protection of Personal Data and guarantee of digital rights. The study was granted regulatory classification as EPA-AS by the Spanish competent authority (AEMPS) on September 4th, 2020, and IEC approval (ref: 2020\/343) by the Ethics Committee of Galicia on September 30th, 2020.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients signed the informed consent form prior to their inclusion in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Exemption of informed consent was applied to those patients that were dead before study initiation to avoid potential selection bias.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}